PBPK Applications (MIFD) Using the Simcyp™ Simulator eBook 使用 Simcyp™ Simulator 的 PBPK 应用(MIFD) Explores strategies, regulatory validation, and solutions in small-molecule human Physiologically Based Pharmacokinetic modeling (PBPK).Simona Colucci2024 年 8 月 28 日
Certara’s Integrated, Compliant Clinical Data Solution From Trial to Regulatory Submission Guide Certara 从试验到监管提交的综合、合规临床数据解决方案 点击以下任一步骤,了解更多信息。Danielle Pillsbury2024 年 8 月 28 日
DMDG in vivo ADME one-day meeting 2024 Conference 2024 DMDG 体内药代动力学(ADME)一日会议 Danielle Pillsbury2024 年 8 月 27 日
《降低通胀法案》对生物类似药市场有何影响? 博客 《降低通胀法案》对生物类似药市场有何影响? The Inflation Reduction Act (IRA), one of the key legislative achievements the Biden-Harris administration, aims…Certara2024 年 8 月 27 日
FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies Article FDA 对 Lykos 的拒绝延缓了迷幻疗法的发展 — 但并未阻止其步伐 Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…Certara2024 年 8 月 26 日
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator Publication 预测涉及抑制作用的 CYP 介导的 DDIs:满足 Simcyp Simulator 系统鉴定要求的方法 The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…Danielle Pillsbury2024 年 8 月 26 日
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) Publication Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…Danielle Pillsbury2024 年 8 月 26 日
The Uncertain Path Forward for Psychedelic Medicine Article The Uncertain Path Forward for Psychedelic Medicine Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…Certara2024 年 8 月 26 日